Article Text

other Versions

PDF
Association of adiponectin multimers with Barrett’s esophagus
  1. Joel H Rubenstein (jhr{at}umich.edu)
  1. University of Michigan, United States
    1. John Y Kao (jykao{at}umich.edu)
    1. University of Michigan, United States
      1. Ryan D Madanick (ryan_madanick{at}med.unc.edu)
      1. University of North Carolina, United States
        1. Min Zhang (minzhang{at}umich.edu)
        1. University of Michigan, United States
          1. Meizhi Wang
          1. University of Michigan, United States
            1. Melissa B Spacek (melissa_brennen{at}med.unc.edu)
            1. University of North Carolina, United States
              1. Jena L Donovan
              1. University of Michigan, United States
                1. Stephanie D Bright (stephanie_bright{at}med.unc.edu)
                1. University of North Carolina, United States
                  1. Nicholas J Shaheen (nshaheen{at}med.unc.edu)
                  1. University of North Carolina, United States

                    Abstract

                    Objective: Barrett's esophagus is associated with abdominal obesity. Adiponectin is a peptide that is secreted from adipocytes and circulates in three multimeric forms: low molecular weight (LMW), middle molecular weight (MMW), and high molecular weight (HMW). The anti-inflammatory effects of adiponectin are specific to individual multimers, with LMW being most anti-inflammatory. We postulated that circulating levels of adiponectin and its multimers would be associated with the risk of Barrett's esophagus.

                    Design: Cross-sectional study.

                    Setting: Outpatient clinic in North Carolina, U.S.A.

                    Patients: Cases of Barrett's esophagus and controls undergoing upper endoscopy for gastroesophageal reflux disease (GERD).

                    Main outcome measures: Adjusted odds ratios of plasma adiponectin levels and its multimers for Barrett's esophagus.

                    Results: There were 112 cases of Barrett's esophagus and 199 GERD controls. Total adiponectin was not associated with Barrett's esophagus (3rd tertile vs. 1st tertile adjusted odds ratio [aOR] = 0.88; 95% confidence interval [CI] = 0.44, 1.78). High levels of LMW adiponectin were associated with a decreased risk of Barrett's esophagus (3rd tertile vs. 1st tertile aOR = 0.33; 95% CI = 0.16, 0.69), and a high LMW/total ratio appeared particularly inversely associated with Barrett's esophagus (3rd tertile vs. 1st tertile aOR = 0.27; 95% CI = 0.13, 0.58).

                    Conclusions: High levels of LMW adiponectin are associated with a decreased risk of Barrett's esophagus among patients with GERD. Further human studies are required to confirm these findings, and in vitro studies are needed to understand if there is a mechanism whereby adiponectin may affect Barrett's metaplasia.

                    Statistics from Altmetric.com

                    Request permissions

                    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                    Linked Articles